CORAL - COVID-19 Second Generation Vaccine
From Our Pipeline
Gritstone is developing a second generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency, including against emerging Spike mutant forms of SARS-CoV-2.
-
Most popular related searches
Products Details
Through a license agreement with the La Jolla Institute for Immunology (LJI), one of the leading global organizations dedicated to studying the immune system, we have access to validated SARS-CoV-2 antigens that have been identified through LJI’s studies of hundreds of patients recovering from COVID-19. Using these antigens and our proprietary Gritstone EDGE™ and vaccine platform technologies, Gritstone has developed a novel vaccine containing Spike (similar to first generation vaccines) but also additional viral antigens that offer good targets for T cell immunity. By targeting several viral antigens, some of which are highly conserved between viral strains (such as SARS and SARS-CoV-2), our vaccine may have pan-SARS/coronavirus potential to protect against future coronavirus pandemics.
Gritstone has conducted preclinical studies demonstrating that our SARS-CoV-2 vaccine can induce significant and sustained levels of neutralizing antibodies and T cells against the Spike protein, plus a broad T cell response against epitopes from multiple viral genes outside of Spike. Positive preclinical data from a non-human primate study from the CORAL program were published in November 2021. As of January 2022, Gritstone expects to share data from its Phase 1 CORAL-BOOST study in 1Q2022.
We have received a grant from the Bill and Melinda Gates Foundation to support the preclinical evaluation of the vaccine. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is supporting the Phase 1 clinical trial, which is being conducted through the Infectious Diseases Clinical Research Consortium (IDCRC). We also have an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) that provides funding to conduct a Phase 1 clinical trial of Gritstone’s vaccine candidate in South Africa.
Customer reviews
No reviews were found for CORAL - COVID-19 Second Generation Vaccine. Be the first to review!